Francis Dowling

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Anti-tumor necrosis factor treatment from diagnosis is more effective and less costly than conventional "step-up" care for patients with active Crohn's disease: a cost-effectiveness analysis from the PROFILE trial.

Anti-tumor necrosis factor treatment from diagnosis is more effective and less costly than conventional "step-up" care for patients with active Crohn's disease: a cost-effectiveness analysis from the PROFILE trial.

Journal: Journal of Crohn's & colitis

Published: October 22, 2025

The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: July 10, 2025

The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.

The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: July 10, 2025

A pragmatic, randomised, open-label, multi-centre UK registry-facilitated trial evaluating the effect of high-dose cholecalciferol on mortality in patients on dialysis: the SIMPLIFIED trial.

A pragmatic, randomised, open-label, multi-centre UK registry-facilitated trial evaluating the effect of high-dose cholecalciferol on mortality in patients on dialysis: the SIMPLIFIED trial.

Journal: Trials

Published: June 12, 2025

Prophylaxis for renal patients at risk of COVID-19 infection: results from the intranasal niclosamide randomised, double blinded, placebo controlled arm of the PROTECT-V platform trial.

Prophylaxis for renal patients at risk of COVID-19 infection: results from the intranasal niclosamide randomised, double blinded, placebo controlled arm of the PROTECT-V platform trial.

Journal: BMC infectious diseases

Published: March 18, 2024

A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.

A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.

Journal: The lancet. Gastroenterology & hepatology

Published: January 25, 2024

PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V).

PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V).

Journal: Trials

Published: December 11, 2022

Predicting outcomes for Crohn's disease using a molecular biomarker: profile trial.

Predicting outcomes for Crohn's disease using a molecular biomarker: profile trial.

Journal: Clinical medicine (London, England)

Published: October 11, 2022

A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.

A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.

Journal: Trials

Published: February 19, 2020

Rating the intelligibility of dysarthic speech amongst people with Parkinson's Disease: a comparison of trained and untrained listeners.

Rating the intelligibility of dysarthic speech amongst people with Parkinson's Disease: a comparison of trained and untrained listeners.

Journal: Clinical linguistics & phonetics

Published: May 01, 2019

Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial.

Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial.

Journal: BMJ open

Published: February 18, 2019

Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2).

Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2).

Journal: Trials

Published: January 07, 2019

Showing 1-12 of 17

Last Updated: 09/26/2026